1 |
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003: 61: 1115-1117.
DOI
ScienceOn
|
2 |
Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998: 19: 80-100.
DOI
ScienceOn
|
3 |
Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002: 4: 30-34.
DOI
|
4 |
Green J, Clezardin P. The molecular basis of bisphosphonate activity: a preclinical perspective. Semin Oncol 2010: 37 Suppl 1: S3-11.
DOI
|
5 |
Rondeau JM, Bltsch F, Bourgier E. et al. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem 2006: 1: 267-273.
DOI
ScienceOn
|
6 |
Green JR. Bisphosphonates: preclinical review. Oncologist 2004: 9 Suppl 4: 3-13.
|
7 |
Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg 2009: 67: 2-12.
|
8 |
Gibbs SD, O'Grady J, Seymour JF. Prince HM. Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention. Med J Aust 2005: 183: 549-550.
|
9 |
Nase JB, Suzuki JR Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc 2006: 137: 1115-1119; quiz 1169-1170.
DOI
|
10 |
Kanat O, Ozet A, Ataergin S, et al. Bisphosphonate treatment as a cause of jaw osteonecrosis. Oral Dis 2007: 13: 346-347.
DOI
ScienceOn
|
11 |
Infante Cossio P, Cabezas Macian A, Perez Ceballos JL. Palomino Nicas J. Gutierrez Perez JL. Bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. Med Oral Patol Oral Cir Bucal 2008: 13: E52-57.
|
12 |
Ruggiero SL, Mehrotra B. Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention. and management. Annu Rev Med 2009: 60: 85-96.
DOI
ScienceOn
|